These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 30712414)
1. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer. Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414 [TBL] [Abstract][Full Text] [Related]
2. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. No JH; Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Han JY; Lim JM; Song YS Gynecol Oncol; 2011 Apr; 121(1):8-12. PubMed ID: 21276607 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma. Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270 [TBL] [Abstract][Full Text] [Related]
4. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma. Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983 [TBL] [Abstract][Full Text] [Related]
5. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease. Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435 [TBL] [Abstract][Full Text] [Related]
8. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026 [TBL] [Abstract][Full Text] [Related]
9. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716 [TBL] [Abstract][Full Text] [Related]
10. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316 [TBL] [Abstract][Full Text] [Related]
11. Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma. Li N; Zhong M; Song M Int J Clin Exp Pathol; 2012; 5(7):660-7. PubMed ID: 22977662 [TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512 [TBL] [Abstract][Full Text] [Related]
13. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
14. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer. Ma BL; Shan MH; Sun G; Ren GH; Dong C; Yao X; Zhou M Mol Med Rep; 2015 Oct; 12(4):5246-54. PubMed ID: 26151180 [TBL] [Abstract][Full Text] [Related]
16. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy. Nishikawa M; Miyake H; Harada K; Fujisawa M Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. Qu Y; Zhao R; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D Sci Rep; 2016 Mar; 6():23594. PubMed ID: 27026382 [TBL] [Abstract][Full Text] [Related]
18. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition. Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437 [TBL] [Abstract][Full Text] [Related]
20. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]